PACAP is Implicated in the Stress Axes

Hitoshi Hashimoto¹ ³ ⁶, Norihiro Shintani¹, Mamoru Tanida⁴, Atsuko Hayata², Ryota Hashimoto² ⁵ and Akenichi Baba¹ ⁶

¹Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan, ²Center for Child Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan, ³Department of Molecular Pharmaceutical Science, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan, ⁴Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1 Nojitagashi, Kusatsu, Shiga 525-8577, Japan, ⁵Department of Psychiatry, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan, ⁶Hyogo University of Health Sciences, 1-3-6 Minatojima, Chuo-ku, Kobe, Hyogo 650-8530, Japan

Abstract: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a highly conserved pleiotropic neuropeptide that functions as a neurotransmitter, neuromodulator and neurotrophic factor. Accumulating evidence implicates PACAP as an important regulator of both central and/or peripheral components of the stress axes, particularly exposure to prolonged or traumatic stress. Indeed, PACAP and its cognate receptors are widely expressed in brain regions and peripheral tissues that mediate stress-related responses. In the sympathoadrenomedullary system, PACAP is required for sustained epinephrine secretion during metabolic stress. It is likely that PACAP regulates autonomic function and contributes to peripheral homeostasis by maintaining a balance between sympathetic and parasympathetic activity, favoring stimulation of the sympathetic system. Furthermore, PACAP is thought to act centrally on the paraventricular nucleus of the hypothalamus to regulate both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Intriguingly, PACAP is also active in brain structures that mediate anxiety- and fear-related behaviors, and the expression of PACAP and its receptors are dynamically altered under pathologic conditions. Thus PACAP may influence both hard-wired (genetically determined) stress responses and gene-environment interactions in stress-related psychopathology. This article aims to overview the molecular mechanisms and psychiatric implications of PACAP-dependent stress responses.

Keywords: Hypothalamic-pituitary-adrenal (HPA) axis, PACAP, paraventricular nucleus (PVN) of the hypothalamus, post-traumatic disorder (PTSD), psychiatric disorders, stress, sympathoadrenomedullary system, sympathetic nervous system.

INTRODUCTION

Stress is defined as a state of threat, or perceived threat to homeostasis and can be classified under four main categories: 1) physical stressors; 2) psychological stressors that reflect a learned response to previously experienced adverse conditions; 3) social stressors reflecting disturbed interactions among individuals; and 4) stressors that challenge cardiovascular and metabolic homeostasis [1, 2]. Adaptation to stressful stimuli is a priority for all organisms and involves the activation of specific central circuits. Adaptive responses are genetically and constitutionally programmed ("hardwired") and are constantly modulated by environmental factors ("gene-environment interaction"). Stress axes comprising the sympathoadrenal and sympathoneuronal systems and the hypothalamic-pituitary-adrenocortical axis, respond to different types of stressors and exhibit stressor-specific response patterns [1-3].

Neuropeptides tend to exert a long-lasting modulatory effect on the small-molecule neurotransmitters with which they colocalize, by regulating the response times of second messenger systems [4]. Thus, neuropeptides are important for adaptation of the nervous system to pathophysiological conditions. The neuropeptide, pituitary adenylate cyclase-activating polypeptide (PACAP), has long been recognized as an important regulator of central and peripheral components of the stress axes, as outlined in Table 1.

PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)

PACAP was first identified as a novel hypothalamic neuropeptide in 1989 by Miyata et al., based on its ability to stimulate adeny-
Table 1. PACAP-dependent Stress Responses

| Effect or Implication of PACAP | References |
|-------------------------------|------------|
| BNST | Dramatic increase in PACAP and BDNF mRNA expression by chronic unpredictable stress | [38, 39] |
| Amygdala | Stress-related behaviors induced by infusion of PACAP into the central nucleus of the amygdala | [42] |
| HPA axis | Stimulation of CRF gene expression in the PVN | [9, 23, 28, 37] |
| | Stimulation of pro-opiomelanocortin gene expression and adrenocorticotropic release | [5, 29-31] |
| | Activation of vasopressin-containing neurons in the supraoptic nucleus and plasma vasopressin secretion | [10, 32-34] |
| | Impairment of stress-induced corticosterone secretion in PACAP-deficient mice | [23] |
| | Acute stress-related behaviors and increased plasma corticosterone induced by intracerebroventricular injection of PACAP | [37] |
| Sympathoadreno-medullary system | Sustained epinephrine secretion during prolonged stress by enhancement of compensatory catecholamine synthesis | [21, 23, 24] |
| Autonomic nervous system | Stimulation of sympathetic outflow | [26] |
| | Maintenance of a sympathetic-parasympathetic balance | |
| PTSD | Female-specific association of the PACAP–PAC1 receptor pathway with PTSD | [51] |

BDNF: brain-derived neurotrophic factor
BNST: bed nucleus of the stria terminalis
HPA: hypothalamic-pituitary-adrenal axis
PTSD: post-traumatic stress disorder
PVN: paraventricular nucleus of the hypothalamus

higher amount of PACAP has also been detected in hypophysial portal blood compared with peripheral blood [11].

PACAP and PACAP receptors are also widely distributed in brain areas outside the hypothalmo-hypophysis known to be involved in stress responses, including the medial prefrontal cortex, hippocampus, amygdala, bed nucleus of the stria terminalis (BNST) and adrenal gland [6, 8, 12-14].

PAC1 receptor mRNA is generally the most widely and abundantly expressed of the three PACAP receptor subtypes, although there are exceptions, for example VPAC1 receptor mRNA is abundantly expressed in hippocampal pyramidal neurons [15] and VPAC2 receptor mRNA is abundantly expressed in the central amygdala [16].

At a subcellular level, PACAP-immunoreactivity appears to be concentrated within neuronal cell bodies and dendrites. Ultrastructurally, it is noteworthy that immunostaining for the PAC1 receptor revealed its presence on synaptic membranes [13].

Detailed anatomical information regarding stress responses are discussed in the following sections.

PACAP-DEPENDENT STIMULATION OF THE SYMPATHOADRENO-MEDULLARY SYSTEM

Many studies have focused on the role of PACAP in the sympathoadrenomedullary system. Retrograde tracing studies with the cholera toxin B subunit have shown that PACAP is expressed in various hypothalamic and extrahypothalamic regions, and in the catecholaminergic neurons of the brain stem that innervate the PVN and the intermedialateral cell column of the spinal cord [17, 18]. Additionally, sympathetic preganglionic neurons projecting to the adrenal medulla contain PACAP [19, 20].

PACAP is postulated to function as an "emergency response" cotransmitter in the sympathoadrenal axis during metabolic stress, by ensuring sustained secretory responses [21]. During insulin-induced hypoglycemia, PACAP-deficient mice exhibit impaired long-term secretion of epinephrine due to defective compensatory stimulation of catecholamine biosynthesis [21]. In addition, adaptive thermogenesis is impaired in PACAP-deficient mice subjected to prolonged periods of cold stress, due to insufficient norepinephrine stimulation of brown adipose tissue [22]. Furthermore, synthesis of adrenaline-synthesizing enzymes in the adrenal medulla is decreased in PACAP-deficient mice subjected to a psychological stressor such as restraint stress, suggesting that PACAP is a key neuroendocrine factor in the hypothalamus and adrenal gland [23]. In adrenal chromaffin cells, PACAP exerts a stimulatory effect on catecholamine secretion, which is associated with increased expression of catecholamine biosynthetic enzyme genes [24].

PACAP-DEPENDENT STIMULATION OF OTHER SYMPATHETIC PATHWAYS

The demonstration of preproPACAP within the sympathetic preganglionic neurons that innervate the adrenal gland, and in those at level C8-T10 of the spinal cord, suggests that PACAP is widely distributed in the sympathetic nervous system [20]. PAC1 receptor mRNA is intensely expressed in virtually all principal neurons of the sympathetic superior cervical ganglia, whereas it suppresses parasympathetic nerve activities [26]. These results suggest that PACAP regulates autonomic function and contributes to peripheral homeostasis by maintaining a balance between sympathetic and parasympathetic activity [26].

PACAP-DEPENDENT STIMULATION OF THE HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) SYSTEM

Immunohistochemical studies have revealed that a significant proportion of PACAP-immunoreactive neurons in the PVN co-
express corticotropin-releasing factor (CRF) [9]. Electron microscopic studies have revealed the presence of synapses between PACAP-containing terminals and CRF-perikarya and -dendrites [27]. PACAP injected intracerebroventricularly activates CRF gene expression in the rat PVN [28], while intravenously infused PACAP induces a dose-dependent increase in serum adrenocorticotropic hormone levels in human [29]. In vitro, PACAP increases adrenocorticotropic hormone release from superfused rat pituitary cells [5] and the pro-opiomelanocortin gene expression in the mouse corticotropedepleted cell line AtT20 [30, 31]. Intracerebroventricular and intracisternal injection of PACAP also increases plasma vasopressin secretion [32, 33]. PACAP is localized in nerve terminals that innervate vasopressin-containing neurons, and PAC1 receptor mRNA is highly expressed in vasopressin-containing neurons in the rat hypothalamic supraoptic nucleus [10]. In the posterior pituitary, PACAP stimulates the release of vasopressin through the cAMP signalling pathway [34]. Together, these data provide strong evidence that PACAP is involved in the activation of the HPA axis.

PACAP-deficient mice show a decrease in corticosterone secretion in response to trimethyltin exposure [35], restraint stress [23], or light following constant darkness [36]. Corticosterone secretion elicited by restraint stress is more severely impaired in PACAP-deficient mice, especially when the stress is prolonged [23]. The increase in hypothalamic mRNA expression of Egr1 (early growth response 1), c-Fos (FBJ osteosarcoma oncogene), and CRF seen with restraint stress, is much less pronounced in PACAP-deficient mice than in wild-type mice [23]. Taken together, these results suggest that PACAP plays an important role in the activation of hypothalamic neurons, in order to regulate the HPA axis response to stress.

MECHANISTIC INSIGHTS INTO PACAP-DEPENDENT STRESS RESPONSES AND IMPLICATIONS FOR PSYCHIATRIC DISORDERS

It has been demonstrated that intracerebroventricular injection of PACAP induces acute stress-related behaviors in rodents (e.g. body grooming and wet-dog shakes), which are associated with an elevation in plasma corticosterone levels and activation of cAMP response element-mediated CRF gene transcription [37].

Intriguingly, chronic unpredictable stress dramatically increases mRNA expression of PACAP and brain-derived neurotrophic factor (BDNF) in the dorsal part of the BNST, a region of the central extended amygdala that mediates fear- and anxiety-like behavior. Moreover, intra-BNST infusion of PACAP induces an anxiogenic response [38]. These findings implicate PACAP in stress-induced increases in BNST neuroplasticity and in long-term stress-induced behavioral changes [39]. Since BDNF expression is stimulated by PACAP [40], and is decreased in PAC1 receptor-deficient mice [41], PACAP-stimulated BDNF expression may underlie the dorso-lateral BNST cellular plasticity associated with anxiety and behavior disorders [38,39]. Infusion of PACAP into the central nucleus of the amygdala has also been shown to induce stress-related behaviors [42].

PACAP-deficient mice exhibit remarkable behavioral abnormalities, and can be regarded as an animal model of psychotic behavior and depression [43-46]. Genetic association studies have provided evidence that single nucleotide polymorphisms in the PACAP gene are associated with an increased risk for schizophrenia [47] or major depressive disorders [48]. In addition, PACAP increases expression of disrupted in schizophrenia 1 (DISC1), which is recognized as a leading candidate risk gene for schizophrenia, and markedly but transiently decreases the association between DISC1 and the DISC1-interacting protein DBZ [49]. These data suggest that PACAP signaling might contribute to the pathogenesis of psychiatric disorders.

It is widely accepted that inadequate response and/or prolonged exposure to stressors may result in psychiatric disorders [1-3]. It is therefore plausible that altered PACAP signaling systems may be involved in the etiology of stress-related psychiatric conditions. Maladaptive stress responses (either in hyperfunctional or hypo-functional states), and subsequent development of disease symptoms, involve an interplay of genetic factors and environmental adversity during critical periods characterized by increased vulnerability to stressors [1-3]. Indeed, PACAP-deficient mice housed alone for a two-week period from 4-weeks of age are more aggressive, but otherwise normal. Furthermore, correction of abnormal behavior by rearing mutant mice for 4 weeks in an enriched environment is effective when carried out from 4-weeks of age, but is ineffective when carried out from 8-weeks of age [50].

Finally, an important study by Ressler and colleagues [51] has shown a female-specific association of the PACAP–PAC1 receptor pathway with post-traumatic stress disorder (PTSD). Ressler et al. demonstrated that PTSD diagnosis was associated with peripheral blood levels of PACAP in females (higher levels in the PTSD cohort), and that an SNP in a putative estrogen response element of the PAC1 receptor gene, rs2267735, was associated with PTSD diagnosis, the severity of symptoms, and with PAC1 receptor messenger RNA expression in the brain. In this report, they also revealed that PACAP and PAC1 receptor mRNA levels were inversely correlated in the human cortex, suggesting that brain levels of PACAP peptide and PAC1 mRNA are tightly regulated [51]. In support, it has been shown that, in rat primary hippocampal neurons, selective serotonin reuptake inhibitors up-regulate PACAP expression and down-regulate PACAP receptor (PAC1 and VPAC2) expression, while the tricyclic antidepressant imipramine shows an opposite effect [52]. In addition, in mice chronically treated with phencyclidine, an N-methyl-D-aspartic acid receptor antagonist, PACAP mRNA is reduced, while PAC1 receptor mRNA is increased in the frontal cortex [47]. These data suggest that the expression of PACAP peptide and PAC1 receptors are actively regulated under physiologic and pathologic conditions, and that perturbations in the PACAP–PAC1 pathway are involved in abnormal stress responses underlying psychiatric conditions such as PTSD [51].

CONCLUSIONS AND OUTLOOK

PACAP and its cognate receptors are widely expressed in brain regions and peripheral tissues known to be involved in the stress axes, and their expression levels may be dynamically altered under pathologic conditions. Convergent evidence implicates PACAP in stress-related responses, particularly during exposure to persistent stress. Under stressful conditions, PACAP coordinates stress signaling in the central and peripheral nervous system [23], and probably acts in concert with other neurotransmitters and neurotrophins. It is intriguing that PACAP also acts on brain structures that mediate anxiety- and fear-related behaviors, where it may influence both hard-wired (genetically determined) stress responses and gene-environment interactions in stress-related psychopathology.

The anxiogenic and/or fear-evoking properties of PACAP must be appropriate and controlled to enable development of a healthy stress response. Further study is required to establish how this neuropeptidergic system is involved in psychopathology under conditions of toxic stress (e.g. prolonged stress and emotional trauma). Future studies addressing the molecular basis and pathophysiologic implications of PACAP-dependent stress responses may facilitate the development of drug therapies for stress.

ACKNOWLEDGMENTS

Our research has been supported, in part, by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science; and the Funding Program for Next Generation World-Leading Researchers.
REFERENCES

[1] Pacak K, Palkovits M. Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. Endocr Rev 2001; 22: 502-48.

[2] Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 2009; 10: 397-409.

[3] Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005; 67: 259-84.

[4] Hashimoto H, Shintani N, Baba A. Higher brain functions of PACAP and a homologous Drosophila memory gene amnesiac: insights from knockouts and mutants. Biochem Biophys Res Commun 2002; 297: 427-31.

[5] Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-74.

[6] Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009; 61: 283-357.

[7] Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 2000; 21: 619-70.

[8] Koves K, Arimura A, Gorcs TG, Somogyvari-Vigh A. Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. Neuroendocrinology 1991; 54: 159-69.

[9] Hannibal J, Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-74.

[10] Shiboda S, Yada T, Nakajo N, Nakay K, Nakai Y, Arimura A. Pituitary adenylate cyclase-activating polypeptide (PACAP): a novel regulator of vasopressin-containing neurons. Brain Res 1997; 765: 81-90.

[11] Bow RC, Bennie J, Fink G. Pituitary adenylate cyclase-activating peptide-38 (PACAP-38) is released into hypophysial portal blood in the normal male and female rat. J Endocrinol 1994; 142: R1-4.

[12] Hashimoto H, Nogi H, Mori K, et al. Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. J Comp Neurol 1996; 371: 567-77.

[13] Shiboda S, Shuto Y, Somogyvari-Vigh A, et al. Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res 1997; 28: 345-54.

[14] Kozicz T, Vigh S, Arimura A. Axon terminals containing PACAP and VIP-immunoreactivity form synapses with CRF-immunoreactive neurons in the dorsolateral division of the bed nucleus of the stria terminalis in the rat. Brain Res 1997; 767: 109-19.

[15] Ishihara T, Shigemoto R, Mori K, et al. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992; 8: 811-9.

[16] Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994; 135: 2662-80.

[17] Das M, Vihlen CS, Legradi G. Hypothalamic and brainstem sources of pituitary adenylate cyclase-activating polypeptide nerve fibers innervating the hypothalamic paraventricular nucleus in the rat. J Comp Neurol 2007; 500: 761-76.

[18] Farnham MM, Li Q, Goodchild AK, Pilowsky PM. PACAP is expressed in sympathoexcitatory bulbospinal C1 neurons of the brain stem and increases sympathetic nerve activity in vivo. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1304-11.

[19] Holgert H, Holmberg K, Hannibal J, et al. PACAP in the adrenal gland–relationship with choline acetyltransferase, enkephalin and chromaffin cells and effects of immunological sympathectomy. Neuroreport 1996; 8: 297-301.

[20] Kumar NN, Allen K, Parker L, Damanhuri H, Goodchild AK. Neuropeptide coding of sympathetic preganglionic neurons; focus on adrenergically projecting populations. Neuroscience 2010; 170: 789-99.

[21] Hamelink C, Tjurmina O, Damadzic R, et al. Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucocorticoidogenesis. Proc Natl Acad Sci U S A 2002; 99: 461-6.

[22] Gray SL, Yamaguchi N, Vencova P, Sherwood NM. Temperature-sensitive phenotype in mice lacking pituitary adenylate cyclase-activating polypeptide. Endocrinology 2002; 143: 3946-54.

[23] Stroth N, Eiden LE. Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. Neuroscience 2010; 165: 1025-30.

[24] Tonshoff C, Hemmick L, Evinger MJ. Pituitary adenylate cyclase activating polypeptide (PACAP) regulates expression of catecholamine biosynthetic enzyme genes in bovine adrenal chromaffin cells. J Mol Neurosci 1997; 9: 127-40.

[25] Nogi H, Hashimoto H, Hagihara N, et al. Distribution of mRNAs for pituitary adenylate cyclase-activating polypeptide (PACAP), PACAP receptor, vasoactive intestinal polypeptide (VIP), and VIP receptors in the rat superior cervical ganglion. Neurosci Lett 1997; 227: 37-40.

[26] Tanida M, Shintani N, Morita Y, et al. Regulation of autonomic nerve activities by central pituitary adenylate cyclase-activating polypeptide. Regul Pept 2010; 161: 73-80.

[27] Legradi G, Hannibal J, Lechan RM. Pituitary adenylate cyclase-activating polypeptide–nerve terminals densely innervate corticotropic hormone–neurons in the hypothalamic paraventricular nucleus of the rat. Neurosci Lett 1996; 219: 145-8.

[28] Grinevich V, Fournier A, Pelletier G. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on corticotropin-releasing hormone (CRH) gene expression in the rat hypothalamic paraventricular nucleus. Brain Res 1997; 773: 190-6.

[29] Chioida P, Volpi R, Cappetti L, Caffarri G, Magotti MG, Coiro V. Effects of intravenously infused pituitary adenylate cyclase activating polypeptide on adrenohypophyseal Hormone secretion in normal men. Neuroendocrinology 1996; 64: 242-6.

[30] Boutilier AL, Monnier D, Koch B, Loeffler JP. Pituitary adenylate cyclase-activating polypeptide: a hypophysiotropic factor that stimulates proopiomelanocortin gene transcription, and proopiomelanocortin-derived peptide secretion in corticotropic cells. Neuroendocrinology 1994; 60: 493-502.

[31] Aoki Y, Iwasaki Y, Katahira M, Oiso Y, Saito H. Regulation of the rat proopiomelanocortin gene expression in AIT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide. Endocrinology 1997; 138: 1930-4.

[32] Murase T, Kondo K, Otake K, Oiso Y. Pituitary adenylate cyclase-activating polypeptide stimulates arginine vasopressin release in conscious rats. Neuroendocrinology 1993; 57: 1092-6.

[33] Seki Y, Suzuki Y, Baskaya MK, Saito K, Takayasu M, Shibuya M, Sugita K. Central cardiovascular effects induced by intracerebral PACAP in dogs. Am J Physiol 1995; 269: H135-9.

[34] Irie H, Buecher B, Monnier D, Koch B. Evidence for the presence of receptors for pituitary adenylate cyclase-activating polypeptide in the neurohypophysis that are positively coupled to cyclic AMP formation and neurohypophysial hormone secretion. Neuroendocrinology 1996; 64: 153-61.

[35] Morita Y, Yanagida D, Shintani N, et al. Lack of trimethylindolyl (TMI)-induced elevation of plasma corticosterone in PACAP-deficient mice. Ann NY Acad Sci 2006; 1070: 450-6.

[36] Hatanaka M, Tanida M, Shintani N, et al. Lack of light-induced elevation of renal sympathetic nerve activity and plasma corticosterone levels in PACAP-deficient mice. Neurosci Lett 2008; 444: 153-6.

[37] Agarwal A, Halvorson LM, Legradi G. Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene. Brain Res Mol Brain Res 2005; 138: 45-57.

[38] Hammack SE, Cheung J, Rhodes KM, et al. Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminals (BNST): roles for PACAP in anxiety-like behavior. Psychoneuroendocrinology 2009; 34: 833-43.

[39] Hammack SE, Roman CW, Lezak KR, et al. Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminals (BNST) in mediag-
ing the behavioral consequences of chronic stress. J Mol Neurosci 2010; 42: 327-40.

[40] Yaka R, He DY, Phamluong K, Ron D. Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1. J Biol Chem 2003; 278: 9630-8.

[41] Zink M, Otto C, Zorner B, Zacher C, Schutz G, Henn FA, Gass P. Reduced expression of brain-derived neurotrophic factor in mice deficient for pituitary adenylate cyclase activating polypeptide type-I-receptor. Neurosci Lett 2004; 360: 106-8.

[42] Legradi G, Das M, Giunta B, Hirani K, Mitchell EA, Diamond DM. Microinfusion of pituitary adenylate cyclase-activating polypeptide into the central nucleus of amygdala of the rat produces a shift from an active to passive mode of coping in the shock-probe fear/defensive burying test. Neural Plast 2007; 2007: 79102.

[43] Hashimoto H, Shintani N, Tanaka K, et al. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci U S A 2001; 98: 13355-60.

[44] Tanaka K, Shintani N, Hashimoto H, et al. Psychostimulant-induced attenuaton of hyperactivity and prepulse inhibition deficits in Adcyap1-deficient mice. J Neurosci 2006; 26: 5091-7.

[45] Hashimoto H, Hashimoto R, Shintani N, et al. Depression-like behavior in the forced swimming test in PACAP-deficient mice: amelioration by the atypical antipsychotic risperidone. J Neurochem 2009; 110: 595-602.

[46] Yamada K, Matsuzaki S, Hattori T, et al. Increased stathmin1 expression in the dentate gyrus of mice causes abnormal axonal arborizations. PLoS One 2010; 5: e8596.

[47] Hashimoto R, Hashimoto H, Shintani N, et al. Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Psychiatry 2007; 12: 1026-32.

[48] Hashimoto R, Hashimoto H, Shintani N, et al. Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder. Neurosci Lett 2010; 468: 300-2.

[49] Hattori T, Baba K, Matsuzaki S, et al. A novel DISC1-interacting partner DISC1-Binding Zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth. Mol Psychiatry 2007; 12: 398-407.

[50] Ishihama T, Ago Y, Shintani N, et al. Environmental factors during early developmental period influence psychobehavioral abnormalities in adult PACAP-deficient mice. Behav Brain Res 2010; 209: 274-80.

[51] Reseler KJ, Mercer KB, Bradley B, et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 2011; 470: 492-7.

[52] Reichenstein M, Rehavi M, Pinhasov A. Involvement of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors in the mechanism of antidepressant action. J Mol Neurosci 2008; 36: 330-8.